IO Biotech, Inc.
188.0M
$3.53M
-0.63
$-1.45
No price alerts set. Add an alert to get notified!
-0.63
1.29
$-1.45
-203.11%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ACET
Adicet Bio, Inc.
|
$6.90 | -1.29% | -0.41 | $66.24M | 0.09 |
|
CUE
Cue Biopharma, Inc.
|
$0.18 | -1.61% | -0.72 | $13.95M | 0.16 |
|
HOWL
Werewolf Therapeutics, Inc.
|
$1.04 | 2.97% | -0.79 | $50.48M | 1.52 |
|
INKT
MiNK Therapeutics, Inc.
|
$11.44 | 7.02% | 0.00 | $53.70M | 0.00 |
|
KPTI
Karyopharm Therapeutics Inc.
|
$6.32 | 7.30% | -0.58 | $53.96M | -0.80 |
|
NRXP
NRx Pharmaceuticals, Inc.
|
$2.25 | 2.27% | -2.49 | $38.89M | -0.04 |
|
OSTX
OS Therapies Incorporated
|
$1.27 | -6.62% | 0.00 | $44.72M | 0.00 |
|
OTLK
Outlook Therapeutics, Inc.
|
$0.20 | -8.40% | -0.12 | $8.25M | -0.96 |
|
SPRB
Spruce Biosciences, Inc.
|
$63.01 | -10.62% | -1.24 | $36.57M | 0.02 |
* Peer stocks are selected based on market capitalization and sector
$2.79
$0.03
$0.00
0.00%
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
